Malta - English - Medicines Authority

elc group s.r.o. pobrezni 394/12, karlin 186 00 prague 8, czech republic - levodropropizine - syrup - levodropropizine 30 ml/5ml - cough and cold preparations

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - levonorgestrel; ethinylestradiol; ethinylestradiol; levonorgestrel; levonorgestrel - tablet - *** awaiting value *** - progestogens and estrogens, sequential preparations; levonorgestrel and ethinylestradiol

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - levonorgestrel; ethinylestradiol; ethinylestradiol; levonorgestrel; levonorgestrel - tablet - milligram(s) - progestogens and estrogens, sequential preparations; levonorgestrel and ethinylestradiol

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - levonorgestrel 1.5mg - tablet - 1.5 mg - active: levonorgestrel 1.5mg excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose poloxamer 188

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - levothyroxine sodium 0.05mg (anhydrous) - tablet - 0.05 mg - active: levothyroxine sodium 0.05mg (anhydrous) excipient: acacia lactose monohydrate magnesium stearate maize starch sodium citrate - levothyroxine is indicated for the treatment of hypothyroidism. this product should only be prescribed to patients already taking this product who are known to be intolerant to all other levothyroxine containing products. this product may also be prescribed to patients already taking this product who are not known to be intolerant to all other levothyroxine containing products, but for whom changing to another levothyroxine containing product is not clinically appropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - levothyroxine sodium 0.1mg (anhydrous) - tablet - 0.1 mg - active: levothyroxine sodium 0.1mg (anhydrous) excipient: acacia lactose monohydrate magnesium stearate maize starch sodium citrate - levothyroxine is indicated for the treatment of hypothyroidism. this product should only be prescribed to patients already taking this product who are known to be intolerant to all other levothyroxine containing products. this product may also be prescribed to patients already taking this product who are not known to be intolerant to all other levothyroxine containing products, but for whom changing to another levothyroxine containing product is not clinically appropriate.

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - levonorgestrel micronized; levonorgestrel micronized; levonorgestrel micronized; ethinylestradiol micronized; ethinylestradiol micronized - coated tablet - percent volume/volume - progestogens and estrogens, sequential preparations; levonorgestrel and ethinylestradiol

Ireland - English - HPRA (Health Products Regulatory Authority)

clear pharma limited - levonorgestrel, ethinylestradiol, levonorgestrel, ethinylestradiol, levonorgestrel, ethinylestradiol - coated tablets - progestogens and estrogens, sequential preparations

European Union - English - EMA (European Medicines Agency)

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - nervous system - levodopa/carbidopa/entacapone orion is indicated for the treatment of adult patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (ddc)-inhibitor treatment.

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - levofloxacin is indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin is indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumoniae, moraxella catarrhalis, chlamydophila pneumoniae, legionella pneumophila, or mycoplasma pneumoniae [see dosage and administration (2.1) and clinical studies (14.2)] . mdrsp isolates are isolates res